Program

version 21 Oct '22
Please note, this program is not yet final and is subject to change.

Sun 30 Oct.

SP1 Plenary lecture

AgRP negative arcuate NPY neuron drive feeding under positive energy balance
Herbert Herzog (Garvan Institute of Medical Research, Australia)

Chair:
Seiji Shioda (Shonan University of Medical Sciences, Japan)

O1 Oral session 1

Chair:
Kazuhiro Takuma (Graduate School of Dentistry, Osaka University, Japan)
Takanobu Nakazawa (Department of Bioscience, Tokyo University of Agriculture, Japan)

Presentations: 15 min in total (12 min talk, 3 min discussion)

1. 11：00-11：15 AM JST
   Secretin Receptor Deletion in the Subfornical Organ Attenuates the Activation of Excitatory Neurons Under Dehydration
   Billy Kwok Chong Chow (The University of Hong Kong)
2. 11：15-11：30 AM JST
   VIP promotes in vitro osteogenic differentiation of a human bone marrow mesenchymal stem cell line
   David Castro-Vázquez (Complutense University of Madrid, Spain)
3. 11：30-11：45 AM JST
   The cytoprotective effect of man-made peptide PT23 with dual activation function for PAC1-R
   Shang Chen (College of Life Science and Technology, Jinan University, China)
4. 11：45 AM-12：00 PM JST
   Novel small molecular positive allosteric modulator of neuropeptide receptor PAC1-R exerts neuroprotective effects in MPTP mouse Parkinson's disease model
   Guangchun Fan (College of Life Science and Technology, Jinan University, China)
5. 12：00-12：15 PM JST
   Targeted stimulation of brainstem NPFF neurons induces a torpor-like state
   Lei Zhang (Garvan Institute of Medical Research, Australia)

S1 Symposium

New horizons of orexin/hypocretin research
More than two decades passed after discovery of novel peptides, orexins/hypocretins. Although orexins/hypocretins were first described as hypothalamic neuropeptides that influence appetite and consciousness, it was later found that orexins/hypocretins also modulate a variety of physiological processes including reward, pain, emotion, and the autonomic regulation of the cardiovascular, respiratory, neuroendocrine, and metabolic systems. In this session entitled “Orexin/Hypocretin”, we assemble cutting edge knowledges of multi-faceted biology of orexin/hypocretin system, look over them with a bird’s-eye view, and to get a new perspective for promoting and further widening the orexins/hypocretins and related research field.

Chair:
Tomoyuki Kuwaki (Graduate School of Medical and Dental Sciences, Kagoshima University, Japan)
Yoichi Ueta (University of Occupational and Environmental Health, Japan)

1. Discovery of orexin receptor agonists
   Tsuyoshi Saitoh (International Institute for Integrative Sleep Medicine, University of Tsukuba, Japan)
2. The orexin system for feeding and sleep/wake behavior
   Takashi Maruyama (University of Occupational and Environmental Health, Japan)
3. The opposite roles of hypothalamic orexin neurons in pain and itch neural processing
   Tatsuroh Kaneko (Graduate School of Medical and Dental Sciences, Kagoshima University, Japan)
4. Recording and manipulation of orexin neuronal activity elucidate its role in sleep/wakefulness regulation
   Akihiro Yamanaka (Chinese Institute for Brain Research, China)

S2 Symposium

Neuropeptide intranasal delivery for treatment of CNS disorders
Systemic approaches often fail to efficiently supply peptides to the CNS because peptides are rapidly degraded and do not always cross the brain blood barrier. Furthermore, peptides receptors are usually not restricted to the brain but also often found in peripheral tissues where they can induce side effects. Thus, over the last couple of years, the interest for intranasal peptide delivery has increased as will be illustrated through different examples in the proposed session that will focus on ‘Neuropeptide intranasal delivery for treatment of CNS disorders’.

Chair:
David Vaudry (Inserm, Normandie University, France)

1. Intranasal delivery of Neuropeptide Y and Galanin agonists for brain disorders related with neurogenesis dysregulation
   Manuel Narváez (Facultad de Medicina, Universidad de Málaga, Spain)
2. Intranasal administration of Pituitary-adenylate cyclase activating polypeptide synthetic analogues ameliorates cognitive function in Huntington’s disease mice
   Xavier Xifró (Medical Science Department, Universitat de Girona, Spain)
3. Brain distribution of incretin receptor agonists following intranasal delivery
   Elizabeth M. Rhea (University of Washington School of Medicine, USA)
4. Intranasal application of agonists of the galanin peptide family
   Barbara Kofler (University Hospital for Pediatrics of the Paracelsus Medical University, Austria)

P1 Poster session 1 (odd numbers)

1. Finding functional gaps: G protein-coupled signalling pathways for VIP receptors
   Alicia Cabrera Martín (Complutense University of Madrid, Spain)
3. Nasal application of α-synuclein decoy peptide protects memory impairment in Lewy body disease-model mice
   Ichiro Kawahata (CNS Drug Innovation, Tohoku University, Japan)
5. Prognostic value of genetic polymorphisms of VPAC receptors in early arthritis
   Amalia Lamana (Faculty of Biology and Medicine, Complutense University, Spain)
7. Neuron-specific overexpression of human VPAC2 receptors in mice causes cognitive dysfunction
   Ami Ono (Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan)
9. Impaired neurodevelopment in iPS cell-derived neural stem cells from psychiatric patients with 7q36.3 microduplication
   Kohei Kitagawa (Graduate School of Pharmaceutical Sciences, Osaka University, Japan)
11. Function of PACAP/PAC1-R System in Stress Response in Zebrafish
    Taiki Nishibe (Graduate School of Science and Engineering, University of Toyama, Japan)
13. Involvement of Spinal and Peripheral PACAP-PAC1 Receptor Signaling System to Itch Sensation in Mice
    Ichiro Takasaki (Graduate School of Science and Engineering for Research, University of Toyama, Japan)
15. Novel small-molecule PAC1 receptor antagonist PA-81004 alleviates fibromyalgia-like pain symptoms in mice
    Yuki Kawabata (Graduate School of Science and Engineering for Research, University of Toyama, Japan)
17. A single oral administration of small-molecule PAC1 antagonist attenuates repeated stress-induced depressive-like behaviors in mice
    Manato Ikuta (Graduate School of Pharmaceutical Sciences, Osaka University, Japan)
19. Chemogenetic inhibition of PACAP neurons projecting to the mPFC exerts antidepressant-like effects
    Yui Yamano (Graduate School of Pharmaceutical Sciences, Osaka University, Japan)
21. Regulation of feeding behavior via neuropeptide network by PACAP in the ventral medial hypothalamus
    Yuki Kambe (Graduate School of Medical and Dental Science, Kagoshima University, Japan)

S3 Symposium

PACAP in the sensory systems
PACAP is present in different parts of the eye and exerts several functions under normal and pathological conditions. Protective effects have been proven in the retina and cornea. Two speakers will present localization, characterization, functions and protective effects of PACAP in the cornea, while two other speakers will demonstrate the latest results on the retinoprotective effects of PACAP: in glaucoma and different pathologies involving retinal vasculature. PACAP is also present in another sensory organ, in the inner ear. One speaker will talk about the most recent results obtained on the alterations in the auditory system of PACAP deficient mice.

Chair:
Dora Reglodi (ELKH-PTE PACAP Research Team, University of Pecs, Hungary)
Tamas Atlasz (ELKH-PTE PACAP Research Team, University of Pecs, Hungary)

1. Localization, characterization and function of pituitary adenylate cyclase-activating polypeptide in the cornea
   Grazia Maugeri (Department of Biomedical and Biotechnological Sciences, University of Catania, Italy)
2. The protective, rescue and DIABETIC RETINOPATHY: ROLE OF PACAP-ADNP AXIS
   Velia D'Agata (Department of Biomedical and Biotechnological Sciences, University of Catania, Italy)
3. Investigation of PACAP1-38 eye-drops treatment in glaucoma
   Evelin Patkó (University of Pecs Medical School, Hungary)
4. The effect of PACAP on retinal vasculature in different disease models
   Tamas Atlasz (ELKH-PTE PACAP Research Team, University of Pécs, Hungary)
5. PACAP in the auditory pathway of wild type and knockout mice
   Daniel Pham (ELKH-PTE PACAP Research Team, Medical School, University of Pécs, Hungary)

A1 Victor Mutt Award Lecture

From Classical Peptide Research to Peptidomics to the Discovery and Clinical Use of Human Blood Peptides: Hemofiltrate is the Comprehensive Source of Innovative Drugs
Wolf-Georg Forssmann (Hannover Medical School, Germany)

Chair:
Karl-Heinz Herzig (University of Oulu Medical School, Finland)

A2 Victor Mutt Award Lecture

Peptides and the Blood-Brain Barrier: A Brain Body Communication Axis
William A Banks (University of Washington School of Medicine, USA)

Chair:
David Vaudry (Inserm, Normandie University, France)

Mon 31 Oct.

P2 Poster session 2 (even numbers)

2. VSAK, a peptide derived from the C-terminal region of CETPI modulates in vivo hyper-inflammatory responses to LPS during sepsis and septic shock
   Jaime Mas-Oliva (Universidad Nacional Autónoma de México)
4. Synthesis of an azacyclopeptide inhibitor of amyloid formation
   Ali EL-Husseini (Department of Chemistry, Université de Montréal, Canada)
6. PAC1 regulates HER4 transactivation in lung cancer cells
   Terry W. Moody (National Institutes of Health, USA)
8. The VIP/VIPR2 pathway regulates breast cancer cell migration
   Satoshi Asano (Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan)
10. Expression pattern and characterization of duplicated zebrafish PACAP/PAC1-Rs
    Tomoya Nakamachi (Faculty of Science, Academic Assembly, University of Toyama, Japan)
12. Distribution of duplicated PACAP and PAC1-R genes in adult zebrafish brain
    Yuuki Yoshida (Graduate School of Science and Engineering, University of Toyama, Japan)
14. Small-molecule PAC1 receptor antagonist PA-81004 prevents the induction of oxaliplatin-induced cold allodynia in mice
    Yuya Ashihara (Graduate School of Pharma-Medical Sciences, Toyama University, Japan)
16. PACAP/PAC1 receptor-evoked astroglial activation contributes to the development of central post-stroke pain
    Yoshimune Sameshima (Graduate School of Medical and Dental Science, Kagoshima University, Japan)
18. Social defeat stress induces activation of PACAP-expressing neurons in thermoregulatory systems
    Yuzuka Fujimoto (Graduate School of Pharmaceutical Sciences, Osaka University, Japan)
20. Effect of pituitary adenylate cyclase-activating polypeptide (PACAP) on heat-stress
    Keisuke Suzuki (Showa University School of Medicine, Japan)

A3 Akira Arimura Award Lecture

Structural biology of peptide-activated G-protein coupled receptors From X-ray crystallography to Cryo-EM
Wataru Shihoya(Department of Biological Sciences, Graduate School of Science, The University of Tokyo, Japan)

Chair:
Hitoshi Hashimoto (Graduate School of Pharmaceutical Sciences, Osaka University, Japan)

M1 Memorial lecture

Memorial Symposium for Dr. Hisayuki Matsuo
Professor Emeritus Hisayuki Matsuo of Miyazaki University passed away on June 8 2022. Dr. Matsuo developed an unique determination method for C-terminal structure of peptides by tritium labeling and played a key role in the discovery of LHRH by Shally of Tulane University, which won the Nobel Prize in Physiology or Medicine in 1977. In addition to contributing to the development of the technology for the structure determination of trace peptides, he also contributed to the development of bioactive peptide research through the isolation and structure determination of a series of opioid peptides such as alpha-neoendorphin, the discovery of novel neuropeptides such as neuromedin B, the discovery of natriuretic peptide family including ANP, the discovery of adrenomedullin and ghrelin. Thus, as a peptide chemist, he left great footprints in the field of bioactive peptide research. Therefore, we would like to organize a memorial symposium in memory of Dr. Matsuo to honor his achievements and to wish for the future development of novel peptide research.

Chair:
Atsuro Miyata (Kagoshima University, Japan)
Kenji Kangawa (Research Institute for Production Development, Japan)

1. Natriuretic Peptides: Present status and Perspective
   Naoto Minamino (National Cerebral and Cardiovascular Center Research Institute, Japan)
2. Translational research on adrenomedullin and adrenomedullin derivatives
   Kazuo Kitamura (Frontier Science Research Center, University of Miyazaki, Japan)
3. Neuromedin U: A trip of memories from its discovery to a great leap forward a multifunctional peptide in Matsuo’s research group
   Masamitsu Nakazato (Faculty of Medicine, University of Miyazaki; Protein Institute, Osaka University, Japan)
4. Ghrelin: for the memory of my mentor Matsuo sensei
   Masayasu Kojima (Institute of Life Science, Kurume University, Japan)

O2 Oral session 2

Chair:
Norihito Shintani (Wakayama Medical University)

Presentations: 15 min in total (12 min talk, 3 min discussion)

1. 2：50-3：05 PM JST
   Is there reproducibility problems in biological research? Illustration with the heterogeneity of response to NGF and PACAP of PC12 cells from different laboratories
   David Vaudry (Inserm, Normandie University, France)
2. 3：05-3：20 PM JST
   Therapeutic efficacy of vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) in amyotrophic lateral sclerosis (ALS) mouse model
   Işıl Tan Yılmaz (Faculty of Medicine, Eskisehir Osmangazi University, Turkey)
3. 3：20-3：35 PM JST
   PACAP neuroprotective effects: focus on antiinvasive role exerts in glioblastoma multiforme
   Agata Grazia D'Amico (Department of Drug Sciences, University of Catania, Italy)

S4 Symposium

The role of bioactive peptides in pain and inflammation
This session deals with the regulatory roles of bioactive peptides in pain and inflammation. Susan D. Brain (U.K.) will talk about the influence of CGRP on acute skin inflammation. Barbara Kofler (Austria) will show the role of the galanin system in inflammation and infection. Éva Borbély (Hungary) will present their latest results relating the mediator effect of hemokinin-1 in different pain conditions. Erika Pintér (Hungary) will provide evidence that SST4 receptor mediates the analgesic anti anti-inflammatory actions of the heptapeptide somatostatin analog TT-232.

Chair:
Erika Pintér (Medical School, University of Pécs, Hungary)

1. The influence of CGRP on acute skin inflammation
   Susan Brain (School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, UK)
2. Role of the galanin system in inflammation and infection
   Barbara Kofler (University Hospital for Pediatrics of the Paracelsus Medical University, Austria)
3. Hemokinin-1 is an important mediator in different pain conditions
   Éva Borbély (University of Pécs, Medical School, Hungary)
4. SST4 receptor mediates the analgesic anti anti-inflammatory actions of the heptapeptide somatostatin analog TT-232
   Erika Pintér (Medical School, University of Pécs, Hungary)

S5 Symposium

The VIP/PACAP-regulated ADNP: from research to therapeutics
The session will highlight recent discoveries in ADNP research, indicating interaction with other key regulatory proteins, revealing fundamental mechanisms in brain development and aging, toward better diagnosis and therapy.

Chair:
Illana Gozes (Sackler Faculty of Medicine and Sagol School of Neuroscience, Tel Aviv University, Israel)
Moran Rubinstein (Sackler Faculty of Medicine and Sagol School of Neuroscience, Tel Aviv University, Israel)

1. The autistic ADNP syndrome and its peptide derivative NAP (davunetide): from research to drug development
   Illana Gozes (Sackler Faculty of Medicine and Sagol School of Neuroscience, Tel Aviv University, Israel)
2. Distinct impairments characterizing different ADNP mutants reveal aberrant cytoplasmic-nuclear crosstalk
   Maram Ganaiem (Sackler Faculty of Medicine and Sagol School of Neuroscience, Tel Aviv University, Israel)
3. Sex-dependent dysregulation of mouse microbiota signature shared by two autism causing ADNP mutations and corrected by the drug candidate NAP (davunetide)
   Alexandra Lobyntseva (Sackler Faculty of Medicine, Sagol School of Neuroscience, Tel Aviv University, Israel)
4. NAP protects from premature death in a mouse model of Dravet syndrome
   Shaked Turk (Faculty of Medicine and Sagol School of Neuroscience, Tel Aviv University, Israel)

SP2 Plenary lecture

Expanding Roles for Galanin in Neuronal Functions: Focus on Human Systems
Tomas Hökfelt (Karolinska Institutet, Sweden)

Chair:
Barbara Kofler (University Hospital for Pediatrics of the Paracelsus Medical University, Austria)

S6 Symposium

Galanin and related peptides – new developments in health and disease
Galanin was first identified 35 years ago as a "classic neuropeptide," with actions primarily as a modulator of neurotransmission in the brain and peripheral nervous system. Other structurally-related peptides-galanin-like peptide, spexin and alarin-with diverse biologic actions in brain and other tissues have since been identified. Over the last decades, in addition to many neuronal actions, a number of nonneuronal actions of galanin peptides have been described. Galanin has been shown to regulate its numerous physiologic and pathophysiological processes through interactions with three G protein-coupled receptors, GAL1, GAL2, and GAL3. In this symposium, we emphasize novel developments in galanin peptide based research.

Chair:
Barbara Kofler (University Hospital for Pediatrics of the Paracelsus Medical University, Austria)
Tomas Hökfelt (Karolinska Institutet, Sweden)

1. Distribution and possible function of galanin in the rat dura mater
   Tadasu Sato (Graduate School of Dentistry, Tohoku University, Japan)
2. An accessory prefrontal cortex- thalamus Galanin+ cell circuit sculpts maternal behavior in virgin female mice
   Daniela D. Pollak (Medical University of Vienna, Austria)
3. Involvement of LRF in antidepressant-like effects of GalR2 in rat ventral hippocampus
   Zhi-Qing David Xu (Capital Medical University, China)

SP3 Plenary lecture

PACAP and stress pathways - from mice to humans
Kerry Ressler (McLean Hospital/ Harvard Medical School, USA)

Chair:
Andrea Tamás (MTA-PTE PACAP Research Team, Medical School, University of Pecs, Hungary)

S7 Symposium

PACAP and davunetide (NAP) in clinical studies
Increasing evidence shows that PACAP levels change under pathological conditions, suggesting the potential clinical use of PACAP as a diagnostic and prognostic biomarker in certain diseases. In this session one of the first results of PACAP studies of stress disorders and the newest results of cardiological disorders and Parkinson’s disease will be presented. In the second part of the session a novel ADNP syndrome mice model will be described. These mice revealed dramatic sex-specific peripheral gene expression with brain synaptic and tau pathologies, partly corrected by davunetide (NAP), now poised for clinical development at ATED Therapeutics.

Chair:
Andrea Tamás (MTA-PTE PACAP Research Team, Medical School, University of Pecs, Hungary)

1. Examination of PACAP in cardiological disorders
   Dóra Szabó (Anatomy Department/ Heart Institute, University of Pecs, Medical School, Hungary)
2. Examination of pituitary adenylate cyclase-activating polypeptide in Parkinson’s disease focusing on correlations with motor symptoms
   Andrea Tamás (MTA-PTE PACAP Research Team, Medical School, University of Pecs, Hungary)
3. Davunetide (NAP): first in the world ADNP syndrome mouse models toward clinical development
   Illana Gozes (Sackler Faculty of Medicine and Sagol School of Neuroscience, Tel Aviv University, Israel)

Tue 1 Nov.

SP4 Plenary lecture

Endogenous peptide ligand recognition and structural transition of Class B GPCRs
Osamu Nureki (Graduate School of Science, The University of Tokyo, Japan)

Chair:
Takashi Kurihara (Graduate School of Medical and Dental Sciences, Kagoshima University, Japan)

S8 Symposium

Small to mid-size molecule ligands for PACAP/VIP receptors
This session will provide topics on the drug discovery of small to mid-size molecule ligands for PACAP/VIP receptors. The first speaker, Dr. Shihoya, recently revealed the Cryo-EM structure of the human PAC1 receptor, providing structural information for PAC1 ligand development. The second and third speakers, Dr. Kurihara and Dr. Shintani, will discuss the antipruritic and antidepressant effects of small molecule antagonists of the PAC1 receptor, respectively. The last speaker, Dr. Ago, will discuss the potential of mid-size molecule antagonists of VPAC2 receptors for the treatment of schizophrenia.

Chair:
Takashi Kurihara (Graduate School of Medical and Dental Sciences, Kagoshima University, Japan)
Ichiro Takasaki (Graduate School of Science and Engineering for Research, University of Toyama, Japan)

1. Cryo-EM structure of the human PAC1 receptor coupled to an engineered heterotrimeric G protein
   Wataru Shihoya (Graduate School of Science, The University of Tokyo, Japan)
2. Both central and peripheral PACAP-PAC1 receptor signaling pathways contribute to itch sensation in mice
   Takashi Kurihara (Graduate School of Medical and Dental Sciences, Kagoshima University, Japan)
3. Fast and lasting antidepressant-like effect of small molecule PACAP receptor PAC1 antagonist
   Yusuke Shintani (Graduate School of Pharmaceutical Sciences, Osaka University, Japan)
4. KS-133, a novel peptide antagonist targeting VIPR2 for the treatment of schizophrenia
   Yukio Ago (Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan)

S9 Symposium

Endocrine and exocrine function of PACAP/VIP and related peptides
In this symposium, the researchers from various fields are gathered together and will talk and discuss on the functional regulation of the endocrine and exocrine systems of VIP, PACAP and related peptides and provide the most recent current topics in each field.

Chair:
Seiji Shioda (Shonan University of Medical Sciences, Japan)
Tomoya Nakamachi (Faculty of Science, Academic Assembly, University of Toyama, Japan)

1. PACAP stimulates social behavior via AVT in zebrafish
   Tomoya Nakamachi (Faculty of Science, Academic Assembly, University of Toyama, Japan)
2. Microbial Changes from Bariatric Surgery Alters Glucose-dependent Insulinotropic Polypeptide and Prevents Fatty Liver Disease
   Tien S. Dong (David Geffen School of Medicine at UCLA, USA)
3. Immune regulation in GALT by immune checkpoint pathways in wild-type and PACAP-deficient mice
   Sparks Jason (ELKH-PTE PACAP Research group, Medical School, University of Pecs, Hungary)
4. PACAP stimulates sweat and salivary secretion acting through water channel AQP5
   Michio Yamashita (Faculty of Pharmacy, Hoshi University, Japan)
5. Molecular Mechanisms Underlying PACAP 38 Induced Neurite Outgrowth in PC12 Cells: Towards OMICS
   Randeep Rakwal (Faculty of Health and Sport Sciences, University of Tsukuba, Japan)

Wed 2 Nov.

M2 Memorial lecture

Dr. Abba J Kastin Memorial Symposium: A Vision of Peptides
William A Banks(University of Washington School of Medicine, USA)

Abba J. Kastin was a pioneer in the field of peptides and passionate about research. He particularly loved the topic of peptides and did much, starting in the 1970’s, to promote their study. Abba either introduced or championed about a dozen key principles that characterized peptides and, a later, regulatory proteins. Some of these principles are exemplified by PACAP and others by peptides that Abba discovered: Tyr-MIF-1 and the endomorphins. In this lecture, I will examine some of those principles as they apply to peptides today and speculate on their future in understanding of peptides and regulatory proteins.

Chair:
Hitoshi Hashimoto (Graduate School of Pharmaceutical Sciences, Osaka University, Japan)

S10 Symposium

Role of PACAP and PAC1 receptors in behavioral functions
This session brings together researchers that are studying the role of the neuropeptide PACAP and its receptor PAC1 in stress, anxiety, pain, and alcohol drinking behaviors. PACAP and PAC1 are critical mediators of stressors of all kinds. Thus, a better understanding of how the central nervous system pathways are engaged by PACAP/PAC1 system is important for developing novel therapeutic avenues for stress and anxiety related disorders.

Chair:
Abha Rajbhandari (Icahn School of Medicine at Mount Sinai, USA)

1. The role of central pituitary adenylate cyclase activating polypeptide (PACAP) signaling in stress and emotion
   Sayamwong E. Hammack (Department of Psychological Science, University of Vermont, USA)
2. PACAP-expressing neurons in the parabrachial nucleus modulate anxiety in alcohol abstinence
   Anel A. Jaramillo (Department of Molecular Physiology and Biophysics, Vanderbilt University, USA)
3. PACAP system of the central amygdala mediates the effects of chronic stress
   Valentina Sabino (Boston University School of Medicine, USA)
4. Title Role of PACAP and PAC1 receptors in stress-related brain and body interactions
   Abha Rajbhandari (Icahn School of Medicine at Mount Sinai, USA)

SP5 Plenary lecture

Pleiotropic function of PACAP: Its role in brain and peripheral organ
Seiji Shioda(Shonan University of Medical Sciences, Japan)

Chair:
Atsuro Miyata (Kagoshima University, Japan)

Pagetop